Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-08

Clinical Trial Update: Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating trametinib in advanced melanoma with BRAF non-V600 mutations; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trametinib (trametinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-08-08